TrialThe oncologist2022

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.

Marla Lipsyc-Sharf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.